Rachel K. King, a Board Member of Novavax, plans to sell 4,150 shares of Common A stock on 12/13/2024. The aggregate market value of the shares to be sold is $37,350. This transaction involves securities acquired through different means.Of the shares to be sold, 700 were acquired through a market purchase on 05/19/2024, with cash payment made through a brokerage account. The remaining 3,450 shares were obtained on 06/25/2021 through an RSU redemption, as part of employment compensation from Novavax.The company's records indicate no securities were sold by the insider during the past three months prior to this announcement. The official notice for this planned transaction was filed on 12/13/2024, coinciding with the proposed sale date.

Rachel K. King, a Board Member of Novavax, plans to sell 4,150 shares of Common A stock on 12/13/2024. The aggregate market value of the shares to be sold is $37,350. This transaction involves securities acquired through different means.Of the shares to be sold, 700 were acquired through a market purchase on 05/19/2024, with cash payment made through a brokerage account. The remaining 3,450 shares were obtained on 06/25/2021 through an RSU redemption, as part of employment compensation from Novavax.The company's records indicate no securities were sold by the insider during the past three months prior to this announcement. The official notice for this planned transaction was filed on 12/13/2024, coinciding with the proposed sale date.